Towards a Data-Driven Approach to Screen for Autism Risk at 12 Months of Age.

autism spectrum disorder first year high-risk parent report screening

Journal

Journal of the American Academy of Child and Adolescent Psychiatry
ISSN: 1527-5418
Titre abrégé: J Am Acad Child Adolesc Psychiatry
Pays: United States
ID NLM: 8704565

Informations de publication

Date de publication:
08 2021
Historique:
received: 06 11 2019
revised: 19 07 2020
accepted: 28 10 2020
pubmed: 9 11 2020
medline: 7 8 2021
entrez: 8 11 2020
Statut: ppublish

Résumé

This study aimed to develop a classifier for infants at 12 months of age based on a parent-report measure (the First Year Inventory 2.0 [FYI]), for the following reasons: (1) to classify infants at elevated risk, above and beyond that attributable to familial risk status for ASD; and (2) to serve as a starting point to refine an approach for risk estimation in population samples. A total of 54 high-familial risk (HR) infants later diagnosed with ASD (HR-ASD), 183 HR infants not diagnosed with ASD at 24 months of age (HR-Neg), and 72 low-risk controls participated in the study. All infants contributed FYI data at 12 months of age and had a diagnostic assessment for ASD at age 24 months. A data-driven, cross-validated analytic approach was used to develop a classifier to determine screening accuracy (eg, sensitivity) of the FYI to classify HR-ASD and HR-Neg. The newly developed FYI classifier had an estimated sensitivity of 0.71 (95% CI: 0.50, 0.91) and specificity of 0.72 (95% CI: 0.49, 0.91). This classifier demonstrates the potential to improve current screening for ASD risk at 12 months of age in infants already at elevated familial risk for ASD, increasing opportunities for detection of autism risk in infancy. Findings from this study highlight the utility of combining parent-report measures with machine learning approaches.

Identifiants

pubmed: 33161063
pii: S0890-8567(20)32060-8
doi: 10.1016/j.jaac.2020.10.015
pmc: PMC8127075
mid: NIHMS1692784
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

968-977

Subventions

Organisme : NICHD NIH HHS
ID : P50 HD103573
Pays : United States
Organisme : NICHD NIH HHS
ID : P50 HD105354
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH116961
Pays : United States
Organisme : NICHD NIH HHS
ID : U54 HD079124
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD055741
Pays : United States
Organisme : NICHD NIH HHS
ID : U54 HD086984
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH118362
Pays : United States

Informations de copyright

Copyright © 2020 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.

Références

Autism Res Treat. 2016;2016:4624829
pubmed: 28116159
J Neurodev Disord. 2015;7(1):24
pubmed: 26203305
J Autism Dev Disord. 2012 Jan;42(1):13-22
pubmed: 21387111
J Autism Dev Disord. 2000 Jun;30(3):205-23
pubmed: 11055457
Lancet Psychiatry. 2015 Feb;2(2):133-40
pubmed: 26359749
J Child Psychol Psychiatry. 2017 Dec;58(12):1330-1340
pubmed: 28393350
Int J Dev Neurosci. 2005 Apr-May;23(2-3):143-52
pubmed: 15749241
MMWR Surveill Summ. 2020 Mar 27;69(4):1-12
pubmed: 32214087
Pediatrics. 2014 Jan;133(1):37-45
pubmed: 24366990
Lancet. 2002 Mar 9;359(9309):881-4
pubmed: 11897304
J Autism Dev Disord. 1994 Oct;24(5):659-85
pubmed: 7814313
Autism. 2018 Apr;22(3):322-334
pubmed: 29671640
J Autism Dev Disord. 2015 Jan;45(1):221-9
pubmed: 25149178
J Autism Dev Disord. 2019 Dec;49(12):4957-4973
pubmed: 31486997
Pediatrics. 2011 Sep;128(3):e488-95
pubmed: 21844053
J Child Psychol Psychiatry. 2020 Jan;61(1):4-17
pubmed: 31032937
J Autism Dev Disord. 2007 Oct;37(9):1691-710
pubmed: 17180716
Nature. 2017 Feb 15;542(7641):348-351
pubmed: 28202961
Sci Transl Med. 2017 Jun 7;9(393):
pubmed: 28592562
Autism Res. 2017 Feb;10(2):224-232
pubmed: 27220677
J Autism Dev Disord. 2009 May;39(5):693-705
pubmed: 19082876
Child Dev. 2013 Mar-Apr;84(2):429-42
pubmed: 23110514
Autism. 2013 Sep;17(5):527-40
pubmed: 22781058
J Autism Dev Disord. 2017 May;47(5):1542-1550
pubmed: 28224344

Auteurs

Shoba S Meera (SS)

Carolina Institute for Developmental Disabilities, University of North Carolina at Chapel Hill; The National Institute of Mental Health and Neurosciences, Bangalore, India. Electronic address: ssmeeras@cidd.unc.edu.

Kevin Donovan (K)

Carolina Institute for Developmental Disabilities, University of North Carolina at Chapel Hill.

Jason J Wolff (JJ)

University of Minnesota, Minneapolis.

Lonnie Zwaigenbaum (L)

University of Alberta, Edmonton, Canada; and the Autism Research Centre, Glenrose Rehabilitation Hospital, Edmonton, Canada.

Jed T Elison (JT)

University of Minnesota, Minneapolis.

Truong Kinh (T)

Carolina Institute for Developmental Disabilities, University of North Carolina at Chapel Hill.

Mark D Shen (MD)

Carolina Institute for Developmental Disabilities, University of North Carolina at Chapel Hill.

Annette M Estes (AM)

University of Washington, Seattle.

Heather C Hazlett (HC)

Carolina Institute for Developmental Disabilities, University of North Carolina at Chapel Hill.

Linda R Watson (LR)

Carolina Institute for Developmental Disabilities, University of North Carolina at Chapel Hill.

Grace T Baranek (GT)

University of Southern California, Los Angeles.

Meghan R Swanson (MR)

University of Texas at Dallas, Richardson.

Tanya St John (T)

University of Washington, Seattle.

Catherine A Burrows (CA)

University of Minnesota, Minneapolis.

Robert T Schultz (RT)

Children's Hospital of Philadelphia, University of Pennsylvania.

Stephen R Dager (SR)

University of Washington, Seattle.

Kelly N Botteron (KN)

Washington University in St. Louis, Missouri.

Juhi Pandey (J)

Children's Hospital of Philadelphia, University of Pennsylvania.

Joseph Piven (J)

Carolina Institute for Developmental Disabilities, University of North Carolina at Chapel Hill.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH